July 18, 2005 -- In a very flat session, biotech traded in negative territory all day, closing almost 23 points lower at 3594.24, a decline of .62%. Geron signed a cancer vaccine deal with Merck, sending its shares 26% higher, Genentech released more positive data on Lucentis, Guidant revealed another problem with its stents, Xoma took an anti-infective back in house, Nymox did not get a recommendation from an FDA advisory board, and Metabasis will resume tests of its diabetes drug. More details...
